5,6-二甲基-1H-咪唑并[4,5-b]吡啶 | 116599-56-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 中文名称: 5,6-二甲基-1H-咪唑并[4,5-b]吡啶
• 英文名称: 5,6-dimethyl-1(3)H-imidazo[4,5-b]pyridine
• 英文别名: 5,6-Dimethyl-1(3)H-imidazo[4,5-b]pyridin；5,6-Dimethyl-1H-imidazo[4,5-b]pyridine
• CAS: 116599-56-5
• 化学式: C₈H₉N₃
• mdl: MFCD21333166
• 分子量: 147.18
• InChiKey: GZHRJZDAOSOXBU-UHFFFAOYSA-N

物化性质

• 熔点：
  220-222 °C (decomp)
• 沸点：
  262.3±23.0 °C(Predicted)
• 密度：
  1.26±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  5,6-dimethyl-1,3-dihydro-imidazo[4,5-b]pyridin-2-one 在 phosphonium iodide 、 五氯化磷 、 氢碘酸 、 三氯氧磷 作用下， 生成 5,6-二甲基-1H-咪唑并[4,5-b]吡啶
  参考文献：
  名称：

  [含氮杂环化合物的合成。十六。2-羟基-5,6-二甲基-7-氮杂-苯并咪唑的制备]

  摘要：

  DOI：

  10.1002/ardp.19582910710

文献信息

• NOVEL PYRIMIDINE COMPOUNDS HAVING BENZYL (HETEROCYCLIC METHYL) AMINE STRUCTURE AND MEDICAMENT COMPRISING THE SAME
  申请人：OHGIYA Tadaaki

  公开号：US20090062306A1

  公开（公告）日：2009-03-05

  A compound represented by the following general formula (I), wherein R 1 , R 2 , R 3 , R 4 and R 5 represent hydrogen atom, a halogen atom, a lower alkyl group and the like, R 6 represents an alkyl group, a cycloalkyl group and the like, R 7 and R 8 represent hydrogen atom, a lower alkyl group, a (lower cycloalkyl)(lower alkyl) group and the like, R 9 represents hydrogen atom, a halogen atom, a lower alkoxy group and the like, R 10 and R 11 represent hydrogen atom, a lower alkyl group, a lower alkoxy group, a halo(lower alkyl) group and the like, and A represents a heterocyclic ring constituted by 6 to 10 atoms, which has potent inhibitory activity on cholesterol ester transfer protein (CETP).

  通式（I）表示的化合物，其中R1、R2、R3、R4和R5表示氢原子、卤原子、低烷基基团等，R6表示烷基基团、环烷基基团等，R7和R8表示氢原子、低烷基基团、（低环烷基）（低烷基）基团等，R9表示氢原子、卤原子、低烷氧基团等，R10和R11表示氢原子、低烷基基团、低烷氧基团、卤代（低烷基）基团等，A表示由6到10个原子构成的杂环环，对胆固醇酯转移蛋白（CETP）具有强大的抑制活性。
• Methods and compositions of treating a flaviviridae family viral infection
  申请人：Einav Shirit

  公开号：US20100028299A1

  公开（公告）日：2010-02-04

  Briefly described, embodiments of this disclosure include compounds, pharmaceutical compositions, methods of treating a host infected with a virus from the Flaviviridae family of viruses, methods of inhibiting HCV replication in a host, methods of inhibiting the binding of NS4B polypeptide to the 3′UTR of HCV negative strand RNA in a host, methods of treating liver fibrosis in a host, and the like.

  简要描述，本公开涉及的实施例包括化合物、制药组合物、治疗感染黄病毒科病毒的宿主的方法、抑制宿主中HCV复制的方法、抑制NS4B多肽与HCV负链RNA的3'UTR结合的方法、治疗宿主肝纤维化的方法等。
• SUBSTITUTED BENZYLAMINO QUINOLINES AS CHOLESTEROL ESTER-TRANSFER PROTEIN INHIBITORS
  申请人：DR. REDDY'S LABORATORIES LTD.

  公开号：US20150216866A1

  公开（公告）日：2015-08-06

  The present invention provides a method for treating or preventing a condition or disease in a human or an animal subject wherein the condition or disease is associated with lipoprotein metabolism, the method comprising administering to the subject a composition comprising benzylamine compounds.

  本发明提供了一种治疗或预防与脂蛋白代谢有关的人类或动物主体的疾病或状况的方法，该方法包括向该主体给予含有苄胺化合物的组合物。
• NOVEL BENZYLAMINE DERIVATIVES AND THEIR UTILITY AS CHOLESTEROL ESTER-TRANSFER PROTEIN INHIBITORS
  申请人：DR. REDDY'S LABORATORIES LTD.

  公开号：US20140134235A1

  公开（公告）日：2014-05-15

  The present invention provides, among other things, new benzylamine compounds, compositions comprising benzylamine compounds, methods of making benzylamine compounds, and methods of using benzylamine compounds for treating or preventing a variety of conditions or diseases associated with lipoprotein metabolism.

  本发明提供了新的苄基胺化合物，包括苄基胺化合物的组合物，制备苄基胺化合物的方法，以及使用苄基胺化合物治疗或预防与脂蛋白代谢有关的各种疾病或症状的方法。
• NOVEL PYRIMIDINE COMPOUND HAVING BENZYL(HETEROCYCLICMETHYL)AMINE STRUCTURE AND PHARMACEUTICAL PRODUCT CONTAINING THE SAME
  申请人：Kowa Company. Ltd.

  公开号：EP2138489A1

  公开（公告）日：2009-12-30

  A compound represented by the following general formula (I), wherein R1, R2, R3, R4 and R5 represent hydrogen atom, a halogen atom, a lower alkyl group and the like, R6 represents an alkyl group, a cycloalkyl group and the like, R7 and R8 represent hydrogen atom, a lower alkyl group, a (lower cycloalkyl)(lower alkyl) group and the like, R9 represents hydrogen atom, a halogen atom, a lower alkoxy group and the like, R10 and R11 represent hydrogen atom, a lower alkyl group, a lower alkoxy group, a halo(lower alkyl) group and the like, and A represents a heterocyclic ring constituted by 6 to 10 atoms, which has potent inhibitory activity on cholesterol ester transfer protein (CETP).

  由以下通式（I）代表的化合物，其中 R1、R2、R3、R4 和 R5 代表氢原子、卤素原子、低级烷基等，R6 代表烷基、环烷基等，R7 和 R8 代表氢原子、低级烷基、（低级环烷基）（低级烷基）等、R9 代表氢原子、卤素原子、低级烷氧基等，R10 和 R11 代表氢原子、低级烷基、低级烷氧基、卤代（低级烷基）基团等，A 代表由 6 至 10 个原子构成的杂环，对胆固醇酯转移蛋白（CETP）具有强效抑制活性。